In the heart of Tokyo, a quiet revolution in oncology and preventive medicine has been underway. NEO Clinic Tokyo leads this transformation, where cancer care moves beyond halting tumor metastasis to embrace the full complexity of each patient’s biology. Integrating state-of-the-art genomic profiling, next-generation immunotherapies, and regenerative techniques, the clinic delivers a personalized model of care that blends science with hospitality, offering a glimpse into the future of precision healthcare. Setting this model apart is the advanced technology it employs and the belief that medicine must move beyond one-size-fits-all cancer treatments. “Now that unprecedented advances in analytical technology have made it possible to analyze cancer genomes, we attempt to provide treatment based on differences in genomic abnormalities,” says Yasuki Hijikata, medical doctor. This philosophy underpins every aspect of patient engagement, from initial consultation through follow -up, ensuring each individual feels heard, understood and supported. The Limits of Standard Therapy and the Genomic Answer Traditional cancer therapies, guided by histopathological analysis, often miss the biological diversity within cancers classified as the same type. Cancer is not a singular disease but an accumulation of genomic abnormalities unique to each patient. Recognizing this, NEO Clinic Tokyo uses whole-genome and exome sequencing—not just targeted gene panels—to design immunotherapies tailored to each tumor’s unique genetic fingerprint. While standard panels yield actionable results in only about 10 percent of cases, broader sequencing uncovers mutations even in non-canonical regions, expanding therapeutic possibilities. Treatments include neoantigen vaccines, immune checkpoint inhibitors, and immune modulators, carefully selected based on exhaustive clinical trial data and AI-assisted analysis. NEO’s approach does not discard conventional therapy—it enhances it, bringing precision to the forefront.
Cell and Gene Therapy
At the heart of today’s bioprocessing breakthroughs are Chinese hamster ovary (CHO) cells— engineered for scale, adaptable by design and trusted for human-like protein expression. Their pivotal role has driven advances in regenerative medicine, biopharmaceuticals and cell therapy over the years. As these fields continue to evolve, the need for reliable, high-yield and cost-effective culture media has never been more critical to sustaining innovation. Shanghai MediumBank Biotechnology is meeting these demands head-on by pushing the boundaries of CHO cell line productivity through AI-driven media development. The company specializes in chemically defined formulations and platform-wide compatibility, delivering end-to-end upstream solutions—from clone screening and media development to process optimization and scale-up support. “By combining AI-driven optimization with our deep bioprocess expertise, we’re setting a new standard in CHO cell culture to help our clients accelerate innovation, ensure quality and reduce development costs,” says Max Wang, CEO. MediumBank champions an agile approach to quality and cost reduction in customizing media. To achieve desired product quality attributes, it integrates quality by design principles, AI analytics and advanced screening technologies. Through its artificial intelligence medium development (AIMD) R&D platform, the company uses a rich formula library, AI analysis and high-throughput screening to develop culture media within one to three months for safer, more effective drugs. Building on this precision, its chemically defined, animal-derived component-free CHO cell culture platform delivers high-performance media for scalable, cost-effective and GMP-compliant biomanufacturing. Validated by over 600 enterprises, this platform marks a forward step by occupying more than 30 percent of China's market share. Pioneering CHO Cell Culture Technology across APAC As a trusted name in APAC bioproduction, MediumBank offers innovative medium optimization and development services. The company delivers media that boost yields by up to 300 percent while reducing development time by 40 percent and costs by 25 percent. Complementing this performance edge, the company also provides OEM media services and supernatant analysis, supporting biopharma from development to commercialization across cell lines such as CHO-K1, CHO-S, CHO-DG44, and CHOZN..
Cell and Gene Therapy
The clinical research landscape is continuously evolving, prompting an important question—what if the next breakthrough therapy could be delivered with unprecedented speed and precision? Advarra is turning this vision into reality, pushing the boundaries of possibilities in medical innovation. Creating a seamless ecosystem that connects patients, research sites, and sponsors accelerates the clinical trial process, ensuring faster and more efficient delivery of life-saving therapies. “Our unique portfolio of technology and services reduces friction by decreasing technology burden, improving study visibility, and enabling smarter decisions that advance clinical research,” says Gadi Saarony, CEO. This comprehensive portfolio includes trusted independent review bodies, cutting-edge technology platforms, and experienced consultancy offerings. Independent review bodies, such as Institutional Review Boards (IRBs), ensure that trials meet regulatory standards and that participant risks are minimized. Federal regulations require that IRBs consist of scientific and non-scientific members tasked with reviewing study materials, including protocols, informed consent forms, investigator credentials, and safety events. In addition to the IRB, other specialized committees, such as Institutional Biosafety Committees (IBCs) and Data Safety Monitoring Boards (DSMBs), contribute to maintaining the safety of clinical research. IBCs ensure the safety of research participants, study staff, and the community by reviewing and assessing biosafety risks associated with cell and gene therapy techniques, particularly those involving genetic modifications. Independent DSMBs are also responsible for monitoring accumulated data to identify potential risks or benefits, offering recommendations to modify or halt the trial when necessary. .
Drug Discovery and Development
Medical Affairs Takes Centre Stage
Dr. Sarah Tregenza, PhD, BSc (Hons), APAC Oncology Medical Affairs Director, Pierre Fabre
Therapeutics
Immunotherapy: Unleashing the Power of the Immune System in Cancer Treatment
Clement Lim, Director, Head of Early Cancer Detection, Scientific & Medical Affairs, Mirxes
Cell and Gene Therapy
Generic Drug Products Development-Challenges and Overview
Suci Ameliya Reza Zairizal, Associate Manager, Novugen
Therapeutics
Creating a Congenial Hospital Space
Janene Lawrence, Clinical Nurse Manager (Medical), Hutt Valley DHB
Therapeutics
Solving The Complexities Of Telehealth Processes For Healthcare Workers
Natalie Yang, Senior Medical Staff Association Chair, Austin Health
IN MY OPINION
Therapeutics
Technology Innovations In Hospital Medication Management
Carol Chow, Head of Pharmacy & Research, Gleneagles Hospital
LAST WORD
Therapeutics
Team Leadership Providing Best Care
Colin Baker, Director Medical Imaging and Pathology Contract, Western Health
IN FOCUS
Japan's Role in Advancing CGT-Immunotherapy-Small Molecule Convergence
Japan's pharmaceutical landscape is evolving through the combination of therapies, including cell and gene therapies, immunotherapies, and small molecules, to enhance treatment efficacy for complex diseases.
Sustainable Biomanufacturing and CHO Cultures in APAC
The APAC biopharmaceutical sector is transitioning towards sustainability, with a focus on reducing the environmental impact of CHO cell cultures through innovative media, equipment, energy efficiency, and waste management strategies.
EDITORIAL
Precision, Compassion, and Innovation: The Future of Life Sciences in Asia-Pacific
This edition of Life Sciences Review APAC examines how forward thinking institutions are combining innovation with purpose. As healthcare systems respond to shifting demographics, rising chronic disease burdens, and digital acceleration, leaders are redesigning care pathways that are proactive, personalized, and rooted in patient experience.
Taking the spotlight in this edition is NEO Clinic Tokyo, renowned for its pioneering work in personalized cancer treatment and regenerative medicine. Under the leadership of Dr. Yasuki Hijikata, the clinic offers a model that integrates whole-genome sequencing, immune reprogramming, and stem-cell-derived therapies. More than just a treatment center, NEO Clinic serves as a sanctuary of healing, blending scientific precision with Japanese hospitality to care for both body and spirit.
Also featured in this issue is Dr. Natalie Yang of Austin Health, who discusses how digital transformation is streamlining clinician workflows and enhancing patient communication within Australia’s public health system. In parallel, Carol Chow of Gleneagles Hospital Hong Kong provides insight into medication automation and the evolving role of pharmacists in managing complex therapies with accuracy and care.
Throughout this issue, readers will discover how the convergence of technology, empathy, and collaboration is redefining healthcare across the region. From cancer immunotherapy to telehealth integration and smart medication management, the message is clear: innovation reaches its full potential when it is guided by the needs of the patient.
We invite you to explore these stories and join the conversation. The future of life sciences is about what we can do with technology and how we choose to use it to heal, connect, and transform lives.
